Association between intravenous iron therapy and short-term mortality risk in older patients undergoing hip fracture surgery: an observational study.
Anemia
Hip fractures
Iron
Mortality
Older people
Journal
Journal of orthopaedic surgery and research
ISSN: 1749-799X
Titre abrégé: J Orthop Surg Res
Pays: England
ID NLM: 101265112
Informations de publication
Date de publication:
18 May 2021
18 May 2021
Historique:
received:
11
03
2021
accepted:
06
05
2021
entrez:
19
5
2021
pubmed:
20
5
2021
medline:
6
10
2021
Statut:
epublish
Résumé
Anemia is common among ortho-geriatric hip fracture patients and is associated with prolonged recovery and increased postoperative mortality rate. Intravenous iron seems to increase hemoglobin recovery and reduce the mortality rate in patients undergoing orthopedic surgeries. This study investigated the association between short-term mortality risk and intravenous iron therapy in older patients undergoing hip fracture surgery. This observational study included 210 patients undergoing hip fracture surgery from July 2018 to May 2020. These 210 patients were alive and had a hemoglobin ≤ 6.5 mmol/L on the 3rd postoperative day. In May 2019, a local intravenous iron therapy protocol was implemented and recommended intravenous iron (Monofer©) if hemoglobin on the 3rd postoperative day was ≤ 6.5 mmol/L. According to the treatment of postoperative anemia between the 1st and 3rd day post-surgery, the patients were divided into four groups: no treatment (n=52), blood transfusion (n=38), IV Monofer (n=80), and blood transfusion and IV Monofer (n=40). Primary outcome was 30-day mortality post-surgery. The secondary outcome was the impact on hemoglobin level 14-30 days postoperatively. Multivariable Cox regression was used to estimate the 30-day mortality standardized for covariates. Of 210 patients, 17 (8.1%) died within 30 days after surgery. There was a significantly lower mortality among the patients who received IV Monofer compared to those who received no treatment (HR 0.17, 95% CI [0.03-0.93], P = 0.041). Among the 86 patients with available hemoglobin measurements within 14 to 30 days post-surgery, there was no significant difference in hemoglobin level between the various treatment groups (mean 6.6 mmol/L, P = 0.1165). IV Monofer on the 3rd postoperative day in older hip fracture patients seemed to reduce 30-day mortality compared with no treatment. No significant differences in hemoglobin levels between 14 and 30 days post-surgery across treatment groups were found, although this was assessed in a subset of patients with available hemoglobin levels warranting further study.
Sections du résumé
BACKGROUND
BACKGROUND
Anemia is common among ortho-geriatric hip fracture patients and is associated with prolonged recovery and increased postoperative mortality rate. Intravenous iron seems to increase hemoglobin recovery and reduce the mortality rate in patients undergoing orthopedic surgeries. This study investigated the association between short-term mortality risk and intravenous iron therapy in older patients undergoing hip fracture surgery.
METHODS
METHODS
This observational study included 210 patients undergoing hip fracture surgery from July 2018 to May 2020. These 210 patients were alive and had a hemoglobin ≤ 6.5 mmol/L on the 3rd postoperative day. In May 2019, a local intravenous iron therapy protocol was implemented and recommended intravenous iron (Monofer©) if hemoglobin on the 3rd postoperative day was ≤ 6.5 mmol/L. According to the treatment of postoperative anemia between the 1st and 3rd day post-surgery, the patients were divided into four groups: no treatment (n=52), blood transfusion (n=38), IV Monofer (n=80), and blood transfusion and IV Monofer (n=40). Primary outcome was 30-day mortality post-surgery. The secondary outcome was the impact on hemoglobin level 14-30 days postoperatively. Multivariable Cox regression was used to estimate the 30-day mortality standardized for covariates.
RESULTS
RESULTS
Of 210 patients, 17 (8.1%) died within 30 days after surgery. There was a significantly lower mortality among the patients who received IV Monofer compared to those who received no treatment (HR 0.17, 95% CI [0.03-0.93], P = 0.041). Among the 86 patients with available hemoglobin measurements within 14 to 30 days post-surgery, there was no significant difference in hemoglobin level between the various treatment groups (mean 6.6 mmol/L, P = 0.1165).
CONCLUSION
CONCLUSIONS
IV Monofer on the 3rd postoperative day in older hip fracture patients seemed to reduce 30-day mortality compared with no treatment. No significant differences in hemoglobin levels between 14 and 30 days post-surgery across treatment groups were found, although this was assessed in a subset of patients with available hemoglobin levels warranting further study.
Identifiants
pubmed: 34006287
doi: 10.1186/s13018-021-02462-x
pii: 10.1186/s13018-021-02462-x
pmc: PMC8130414
doi:
Substances chimiques
Disaccharides
0
Ferric Compounds
0
Hemoglobins
0
iron isomaltoside 1000
3M6325NY1R
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
320Références
Transfusion. 2017 Jun;57(6):1347-1358
pubmed: 28150313
Ann Surg. 2016 Aug;264(2):203-11
pubmed: 27163948
Nutr Hosp. 2005 Mar-Apr;20(2):115-20
pubmed: 15813395
JAMA. 2007 Jun 13;297(22):2481-8
pubmed: 17565082
BMC Geriatr. 2017 Oct 10;17(1):230
pubmed: 29017448
Ann R Coll Surg Engl. 2016 Jul;98(6):380-6
pubmed: 27055406
Vox Sang. 2005 May;88(4):235-43
pubmed: 15877644
Trials. 2013 Sep 09;14:288
pubmed: 24015990
Transfusion. 2016 Sep;56(9):2199-211
pubmed: 27195774
Vox Sang. 2015 Oct;109(3):257-66
pubmed: 25900643
Anesthesiology. 2018 Oct;129(4):710-720
pubmed: 30074935
Transfusion. 2016 Mar;56(3):673-81
pubmed: 26748489
BMC Musculoskelet Disord. 2011 Nov 21;12:262
pubmed: 22104041
Anaesthesia. 2018 Nov;73(11):1418-1431
pubmed: 30062700
Transfusion. 2006 Jul;46(7):1112-9
pubmed: 16836557
Eur J Anaesthesiol. 2018 Apr;35(4):289-297
pubmed: 29303906
J Orthop Trauma. 2004 Jul;18(6):369-74
pubmed: 15213502
Am J Hematol. 2017 Mar;92(3):286-291
pubmed: 28052413
Transfusion. 2014 Feb;54(2):289-99
pubmed: 23581484
Age Ageing. 2019 Sep 1;48(5):751-755
pubmed: 31127269
Geriatr Orthop Surg Rehabil. 2020 Jun 26;11:2151459320935094
pubmed: 32637197
Br J Surg. 1998 Jan;85(1):41-5
pubmed: 9462381
J Trauma. 2003 May;54(5):908-14
pubmed: 12777903
Arch Orthop Trauma Surg. 2005 Jun;125(5):342-7
pubmed: 15789233
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Eur J Intern Med. 2004 Dec;15(8):481-486
pubmed: 15668082
J Arthroplasty. 2016 Feb;31(2):378-82
pubmed: 26391927
Clin Orthop Surg. 2018 Mar;10(1):20-25
pubmed: 29564043
J Bone Joint Surg Am. 2010 Feb;92(2):265-9
pubmed: 20124051
J Surg Res. 2002 Feb;102(2):237-44
pubmed: 11796024
Age Ageing. 2008 Mar;37(2):173-8
pubmed: 18349013
Transfusion. 2011 Jan;51(1):97-104
pubmed: 20630042
Br J Anaesth. 2012 Mar;108(3):532-4
pubmed: 22337966
Clin Orthop Surg. 2019 Sep;11(3):265-269
pubmed: 31475045
Vox Sang. 2012 Oct;103(3):223-30
pubmed: 22540265
Expert Opin Drug Deliv. 2017 Dec;14(12):1439-1446
pubmed: 29032713
Transfusion. 2017 Dec;57(12):3049-3057
pubmed: 29106698
J Clin Epidemiol. 1994 Nov;47(11):1245-51
pubmed: 7722560
J Orthop Trauma. 2002 Jan;16(1):39-44
pubmed: 11782632